Eshelman Fredric N
SEC-identified person · CIK 1033409 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Versartis, Inc. VSAR | Director · Executive Chairman of Board | filed 2020–2022 |
| Hyperion Defi, INC. HYPD | Director | filed 2018–2021 |
| Liquidia Corp LQDA | Officer | filed 2020–2021 |
| Liquidia Technologies Inc LQDA | Officer | filed 2020–2020 |
| G1 Therapeutics, Inc. GTHX | Director | filed 2017–2020 |
| Jasper Therapeutics, Inc. JSPR | Director | filed 2019–2019 |
| Medicines CO /DE MDCO | Director · Executive Chairman | filed 2015–2018 |
| Valeant Pharmaceuticals International, Inc. vrx | Director | filed 2016–2018 |
| Furiex Pharmaceuticals, Inc. FURX | Director | filed 2010–2014 |
| Pharmaceutical Product Development INC PPDI | Director · Executive Chairman | filed 2006–2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.